[{"orgOrder":0,"company":"Nano PharmaSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Apomorphine","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nano PharmaSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nano PharmaSolutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nano PharmaSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Essential Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Essential Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||Adrenergic-alpha receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Essential Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Essential Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||Adrenergic-alpha receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trupharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Trupharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trupharma \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Bial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Bial","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Bial"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Marathon Asset Management"},{"orgOrder":0,"company":"William Ondo, MD","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"William Ondo, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"William Ondo, MD \/ Sumitomo Pharma America","highestDevelopmentStatusID":"11","companyTruncated":"William Ondo, MD \/ Sumitomo Pharma America"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"||Adrenergic-alpha receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Essential Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Essential Pharma"},{"orgOrder":0,"company":"Criceto Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Criceto Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Criceto Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Criceto Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"University of Calgary","sponsor":"PALADIN LABS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Calgary \/ Paladin Labs","highestDevelopmentStatusID":"9","companyTruncated":"University of Calgary \/ Paladin Labs"},{"orgOrder":0,"company":"Alexza Pharmaceuticals","sponsor":"Peachtree BioResearch Solutions | DSG | ISS, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Alexza Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Alexza Pharmaceuticals \/ Peachtree BioResearch Solutions | DSG | ISS, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Alexza Pharmaceuticals \/ Peachtree BioResearch Solutions | DSG | ISS, Inc."},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Autotelic Bio \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic Bio \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"||D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Autotelic Bio \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic Bio \/ Oncotelic Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for Apomorphine Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Nano PharmaSolutions

                          Country arrow
                          EPSC
                          Not Confirmed

                          Nano PharmaSolutions

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 01, 2025

                          Lead Product(s) : NT-301,Apomorphine Hydrochloride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the licensing agreement, Orion will hold the exclusive rights of the Aporon(apomorphine HCl), which is being evaluated for the treatment of OFF episodes in patients with Parkinson’s disease.

                          Product Name : Aporon

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 25, 2025

                          Lead Product(s) : Apomorphine Hydrochloride,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Orion Corporation

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Onapgo (apomorphine) is a novel and less invasive therapy, which acts as dopamine D2 receptor agonist, & is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.

                          Product Name : Onapgo

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 05, 2025

                          Lead Product(s) : Apomorphine Hydrochloride,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SPN-830 (apomorphine) is a novel and less invasive therapy, which acts as dopamine D2 receptor agonist, and is investigated for motor fluctuations (OFF episodes) in Parkinson’s disease.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 04, 2024

                          Lead Product(s) : Apomorphine Hydrochloride,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SPN-830 (apomorphine) is a novel and less invasive therapy, which is acts as dopamine D2 receptor agonist, which is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 10, 2023

                          Lead Product(s) : Apomorphine Hydrochloride,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 07, 2023

                          Lead Product(s) : Apomorphine Hydrochloride,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Peachtree BioResearch Solutions | DSG | ISS, Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SPN-830 (apomorphine) is a novel and less invasive therapy, which is acts as dopamine D2 receptor agonist, which is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 11, 2023

                          Lead Product(s) : Apomorphine Hydrochloride,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Iopidine (apraclonidine hydrochloride), is an alpha2-adrenergic agonist, a sympathomimetic used in glaucoma therapy. It is used as a short-term adjunctive therapy in open-angle glaucoma who are on maximally tolerated medical therapy requiring additional ...

                          Product Name : Iopidine

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 16, 2023

                          Lead Product(s) : Apomorphine Hydrochloride,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : IOPIDINE (apraclonidine hydrochloride), is a short-term adjunctive therapy for chronic glaucoma to prevent or control intraocular pressure including after selective laser therapy, a form of laser eye surgery now recommended as the initial treatment for o...

                          Product Name : Iopidine

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 15, 2022

                          Lead Product(s) : Apomorphine Hydrochloride,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SPN-830 is an investigational apomorphine infusion device under review for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD).

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 10, 2022

                          Lead Product(s) : Apomorphine Hydrochloride,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank